



# Revised Prior Authorization Policy for Pharmacy Providers

---

February 6, 2022

Medi-Cal Rx has implemented a revised prior authorization (PA) policy effective immediately and retrospective to January 1, 2022. **Pharmacies should resubmit claims that were previously denied with Reject Code 75.**

Medi-Cal Rx is temporarily adjusting some PA requirements, as noted below, to optimize access to patient care and therapies during this period of transition.

Please follow the Point-of-Sale (POS) messages. Pharmacies should not prospectively submit PAs **at this time** if the claim is paying.

## Reject Code 75 Edit

Effective immediately, the PA requirement will temporarily be removed for some drugs, except for the following:

1. Psychostimulants – Antidepressants
2. Opioid Analgesics
3. Ataractics – Tranquillizers (including antipsychotics and benzodiazepines)
4. Certain excluded products and for children under the age of 21

PAs may still be required for other reject codes such as quantity limits and Reject Code 76. The existing Price Override Policy remains in place.

**Note: The Contract Drug List (CDL), Drug Lookup Tool (DLT), and ePrescribing file may not reflect this temporary change.**